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Background
The benefit of a transcatheter aortic valve replacement
(TAVR) can differ in patients and therapy bears severe
risks. Dual T1 mapping allows for a comprehensive
assessment of myocardial tissue by quantification of
extracellular volume (ECV) by measuring T1-relaxation
before and after administration of Gadolinium(Gd). High
degree aortic stenosis can lead to cardiac damage such as
diffuse myocardial fibrosis, evaluable by ECV in CMR.
We sought to assess the prognostic value of T1 map-
ping and ECV to predict adverse events during and after
TAVR.
Methods
Since July 2013, we investigated 105 patients undergoing
clinically indicated TAVR by performing additional
CMR with T1 mapping sequences. Examinations were
performed one day before intervention. We used a-
Modified Look Locker Inversion Recovery (MOLLI)
sequence with 3 inversion pulses and a 4-(1)-3-(1)-2
readout pattern. The post Gd scan for extra cellular
volume calculation was performed 10 min. after admin-
istration of a bolus of 0.2 mmol/kg body weight gado-
pentetate dimeglumine. Study endpoints were all cause
death, congestive heart failure (CHF) and TAVR asso-
ciated conduction abnormalities defined as new onset of
left bundle branch block (LBBB), AV-Block or implanta-
tion of a pacemaker.
Results
Median follow-up time was 191 days [IQR 59 - 361
days]. Out of 105 patients 97(92%) could be followed.
During follow up 10 (10%) patients died, 5 (5%) patients
required hospitalization due to CHF, in 17 (18%)
patients a pacemaker was required, in 11(11%) patients
a new onset of a LBBB was observed and 5(5%) patients
had new onset of an AV-Block I. Occurrence of death
and CHF had no statistically relevant association with
BMI, age, gender, EuroScore or type of valve prosthesis,
LV-mass, end diastolic volume, ejection fraction or
fluoroscopy time.
ECV was increased (>30%) in 38 patients (40%).
There was no significant correlation between ECV
and death, Hazard ratio (HR) 0.847[95% CI: 0.335;
2.14], p = 0.72. ECV in patients with subsequent CHF
was higher than in those without an event (33.5 ± 4.6%
and 29.1 ± 4.1% respectively), but the difference just
did not reach the level of significance HR: 2.16[95% CI:
0.969; 4.84], p = 0.06.
Patients with post-TAVR conduction abnormality
(LBBB, AV-block or pacemaker implantation) had statis-
tically relevant lower ECV-values compared to those
without an event. Patients with an event had a mean
ECV of 28.1 ± 3.16%; patients without an event had a
mean ECV of 29.8 ± 4.53, HR: 0.558[95% CI: 0.324;
0.962], p = 0.036.
Conclusions
In this study, elevated myocardial ECV is a predictor of
CHF by trend, CMR may be helpful in identifying patients
with a high risk for post-TAVR cardiac decompensation
2Institute of Diagnostic and Interventional Radiology, Klinikum rechts der Isar,
Technische Universität München, Munich, Germany
Full list of author information is available at the end of the article
Nadjiri et al. Journal of Cardiovascular Magnetic
Resonance 2016, 18(Suppl 1):O64
http://www.jcmr-online.com/content/18/S1/O64
© 2016 Nadjiri et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
benefitting from an intensified postinterventional
surveillance.
Patients with post-TAVR conductions abnormalities
have a significantly decreased ECV. One possible explana-
tion of this phenomenon could be that myocardial fibrosis
may protect the conduction pathways from pressure
caused by the valve prosthesis.
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